Interferon-gamma (IFN-gamma) can enhance the experimental metastatic ability of B16 melanoma. The in vitro treatment with IFN-gamma of four clones derived from the murine mammary adenocarcinoma TS/A increased the number of lung colonies observed after intravenous injection in syngeneic mice. The spontaneous metastatic ability of these clones was not altered by the IFN-gamma pretreatment nor by daily intratumor injection of low-dose IFN-gamma. The experimental metastatic ability in nude mice of the human rhabdomyosarcoma cell line RD was decreased by in vitro pretreatment with IFN-gamma. To study the role played by major histocompatibility complex gene products in the IFN-gamma-mediated enhancement of B16 experimental metastasis, a mutant B16 clone, B78H1, was transfected with the H-2Kb gene. B78H1 cells are not capable of expressing H-2b even after treatment with IFN-gamma; IFN-gamma readily induced high levels of H-2Kb in a set of transfected clones, but did not enhance their experimental metastatic ability.
Get full access to this article
View all access options for this article.
References
1.
ChervenakR., WolcottR.M.: Target cell expression of MHC antigens is not (always) a turn-off signal to natural killer cells. J. Immunol., 140: 3712–3716, 1988.
2.
EisenbachL., KatzavS., HammerlingG., SegalS., FeldmanM.: Gene products of the Major Histocompatibility Complex control the metastatic phenotype of tumor cells. In: Biochemistry and Molecular Genetics of Cancer Metastasis, LapisK., LiottaL.A., RabsonA.S. (eds.), pp. 167–184, Martinus Nijoff, Boston, 1986.
3.
EisenbachL., SegalS., FeldmanM.: MHC imbalance and metastatic spread in Lewis lung carcinoma clones. Int. J. Cancer, 32: 113–120, 1983.
4.
GiovarelliM., CofanoF., VecchiA., ForniM., LandolfoS., ForniG.: Interferon-activated tumor inhibition in vivo. Small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity. Int. J. Cancer, 37: 141–148, 1986.
5.
GopasJ., SegalS., HammerlingG., Bar-EliM., Rager-ZismanB.: Influence of H-2K transfection on susceptibility of fibrosarcoma tumor cells to natural killer (NK) cells. Immunol. Lett., 17: 261–266, 1988.
6.
GrafL.H., KaplanP., SilagiS.: Efficient DNA-mediated transfer of selectable genes and unselected sequences into differentiated and undifferentiated mouse melanoma clones. Somatic. Cell Mol. Genet., 10: 139–151, 1984.
7.
HannaN., BurtonR.C.: Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J. Immunol., 127: 1754–1758, 1981.
8.
KarreK., LjunggrenH.G., PiontekG., KiesslingR.: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature, 319: 675–678, 1986.
9.
LolliniP.L., De GiovanniC., Del ReB., NicolettiG., ProdiG., NanniP.: Interferon-mediated enhancement of metastasis. Are MHC antigens involved? Clin. Exp. Metastas., 5: 277–287, 1987.
10.
LolliniP.L., De GiovanniC., EusebiV., NicolettiG., ProdiG., NanniP.: High-metastatic clones selected in vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line. Clin. Exp. Metastas., 3: 251–259, 1984.
11.
McAllisterR.M., MelnykJ., FinklesteinJ.Z., AdamsE.C.Jr., GardnerM.B.: Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer, 24: 520–526, 1969.
12.
NanniP., ColomboM.P., De GiovanniC., LolliniP.L., NicolettiG., ParmianiG., ProdiG.: Impaired H-2 expression in B16 melanoma variants. J. Immunogenet., 10: 361–370, 1983.
13.
NanniP., De GiovanniC., LolliniP.L., NicolettiG., ProdiG.: TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastas., 1: 373–380, 1983.
14.
NanniP., De GiovanniC., NicolettiG., Del ReB., ScotlandiK., LolliniP.L.: Human rhabdomyosarcoma cells in nude mice as a model for metastasis and differentiation. Invasion Metastasis, 9: 231–241, 1989.
15.
Rager-ZismanB., GopasJ., Bar-EliM., Har-VardiI., HammerlingG.J., SegalS.: NK sensitivity, H-2, c-K-ras proto-oncogene expression and metastasis: analysis of the metastatic potential of H-2 gene transfected fibrosarcoma cells. In: Cancer Metastasis - Biological and Biochemical Mechanisms and Clinical Aspects.ProdiG., LiottaL.A., LolliniP.L., GarbisaS., GoriniS., HellmannK. (eds.), pp. 151–160, Plenum Press, New York, 1988.
16.
RamaniP., BalkwillF.R.: Enhanced metastasis of a mouse carcinoma after in vitro treatment with murine interferon-gamma. Int. J. Cancer, 40: 830–834, 1987.
17.
SouthernP.J., BergP.: Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promotor. J. Mol. Appl. Genet., 1: 327–341, 1982.
18.
TaniguchiK., PeterssonM., HoglundP., KiesslingR., KleinG., KarreK.: Interferon-gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. USA, 84: 3405–3409, 1987.
19.
TrinchieriG., SantoliD.: Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cell to lysis. J. Exp. Med., 147: 1314–1333, 1978.
20.
WexlerH.: Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst., 36: 641–645, 1966.
21.
WiglerM., SweetR., SimG.K., WoldB., PellicerA., LacyE., ManiatisT., SilversteinS., AxelR.: Transformation of mammalian cells with geens from procaryotes and eucaryotes. Cell, 16: 777–785, 1979.
22.
ZoellerM., StrubelA., HaemmerlingG., AndrighettoG., RazA., Ben-Ze'evA.: Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflections by metastatic spread. Int. J. Cancer, 41: 256–266, 1988.
